

# Association of Glycosylated Haemoglobin and Wound Healing in Diabetic Foot Ulcer: A Prospective Cohort Study

OJING KOMUT<sup>1</sup>, MINGGE PERTIN<sup>2</sup>, BINITA SINGHA<sup>3</sup>, TASO BEYONG<sup>4</sup>, OBANG PERME<sup>5</sup>, ABINASH HAZARIKA<sup>6</sup>, TONY ETE<sup>7</sup>, NANI TAGO<sup>8</sup>

#### (CC) BY-NC-ND

## **ABSTRACT**

**Introduction:** Diabetes Mellitus (DM) is a disease that, over time, can affect practically all organ systems in the body, including the skin and circulatory systems. An estimated 15% of all diabetic patients develop a foot ulcer in their lifetime. Although it is clear from the literature review that strict glycaemic control prevents complications, the relationship between Glycosylated Haemoglobin (HbA1c) value and wound healing in diabetic foot patients is less well-defined.

**Aim:** To determine the association between Glycosylated Haemoglobin (HbA1c) and wound healing rate in Diabetic Foot Ulcers (DFUs).

**Materials and Methods:** This prospective cohort study was conducted in the Department of General Surgery, Regional Institute of Medical Sciences (RIMS), Imphal, Manipur, India, between August 2018 and July 2020. All patients between 18 and 70 years old, diagnosed with diabetic foot according to the World Health Organisation definition, and presenting with a lower limb ulcer were included as study participants. A detailed clinical history, examination of the patient, limb, and ulcer, and baseline HbA1c assessment were performed. The ulcer wound was graded and staged according to the University of Texas

Wound classification system. All selected patients were divided into two groups. Group-A (n=15) comprised patients with HbA1c  $\leq$ 7%, and Group-B (n=15) consisted of patients with HbA1c >7%. The primary outcome was the wound healing rate per day in relation to HbA1c levels at baseline and subsequent followup. The secondary outcomes were the demographic profile and predisposing factors affecting the healing of DFUs. Student's t-test (two-tailed, independent) and Chi-square/Fisher's-exact tests were performed for statistical analysis.

**Results:** The mean age of the subjects was  $57.33\pm7.43$  years in Group-A and  $56.20\pm7.51$  years in Group-B. There was a male preponderance in both Group-A (9) and Group-B (11). A total of 11 (36.7%) patients had a history of smoking, all of them being male. The mean healing rate per day was  $0.09\pm0.02$  cm<sup>2</sup>/day in Group-A patients, which is higher compared to Group-B with  $0.02\pm0.01$  cm<sup>2</sup>/day.

**Conclusion:** Strict glycaemic control is a mainstay in preventing the progression of foot ulcers to gangrene and, therefore, amputation. A lower baseline HbA1c at the presentation of DFU is indicative of a favourable outcome in terms of wound healing, with comprehensive treatment and follow-up efforts.

# **INTRODUCTION**

Diabetes is a major public health problem that is approaching epidemic proportions globally. The prevalence of diabetes in India has risen to 8.9% in 2019 [1]. The northeastern states have a prevalence of 6.38% [2]. DM is a disease that, over time, can affect practically all organ systems in the body, including the skin and circulatory systems. An estimated 15% of all diabetic patients develop a foot ulcer in their lifetime [3,4].

Diabetic foot complications remain a major medical, social, and economic problem. Globally, DFU prevalence is 6.3%, with a male (4.5%) preponderance over females (3.5%) [5]. The primary underlying risk factors in the development of foot ulcers were neuropathy and ischaemia, the two common complications of diabetes, while hyperglycaemia contributes to delayed and impaired wound healing [6]. The majority of foot ulcers remain unrecognised at initial stages due to associated neuropathy and ischaemia, and then rapidly progress to a stage where limb salvage becomes difficult, leading to amputation. Consequently, this leads to repeated hospitalisation and economic burden on the patients [7]. In addition to impairment in the quality of life, DFUs are associated with reduced life expectancy, with 5-year mortality rates as high as 55% for ischaemic ulcers and 77% for those with a previous lower limb amputation [8].

Neuropathy in diabetic patients involves the motor, autonomic, and sensory components of the nervous system [9]. Due to the loss of

Keywords: Control, Healing, Hyperglycaemia, Risk factors, Wound

sensation as a part of peripheral neuropathy, patients are unable to detect the trauma occurring in the affected area, which exacerbates the development of ulcers [10]. DFUs, if not managed properly, progress and lead to amputation of the affected foot. Routine monitoring of blood glucose levels is a hallmark of diabetic care with the goal of maintaining a normoglycaemic or near-normoglycaemic level of blood glucose control. The American Diabetes Association has included HbA1c in the diagnosis of DM, with a cut-off value of 6.5 [11]. HbA1c levels are considered as a gold standard measurement of patients' glycaemic control over the previous three months [12].

Many studies conducted by Christman AL et al., Akbar N and Bilal N., Zhao W et al., have shown a positive correlation between glycaemic control and improved wound healing and a lower incidence of limb amputation due to DFUs [13-15]. Although it is clear from the literature that strict glycaemic control prevents complications, the relationship between HbA1c value and wound healing in diabetic foot patients is less well-defined.

Thus, the present study was conducted with the objective to determine the association of HbA1c and wound healing in DFUs. Improving glycaemic control may improve ulcer outcomes. The authors' hypothesised that Group-A patients would have a much better outcome than Group-B patients in terms of wound healing. Therefore, the prediction of outcomes may be helpful for healthcare professionals in individualising and optimising the clinical assessment and management of patients, resulting in improved

health outcomes, improved quality of life, and fewer diabetesrelated foot complications.

### **MATERIALS AND METHODS**

This prospective cohort study was conducted in the Department of General Surgery, Regional Institute of Medical Sciences, Imphal, Manipur, India, between August 2018 and July 2020. The study was carried out after obtaining approval from the Research Ethics Board, Regional Institute of Medical Sciences, Imphal (A/206/REB-Comm(SP)/RIMS/2015/471/89/2018), and strict confidentiality and privacy were maintained.

Inclusion and Exclusion criteria: All patients older than 18 years and less than or equal to 70 years, diagnosed with diabetic foot according to the World Health Organisation definition [16], and presenting with a lower limb ulcer (DFUs grade 1, 2, and 3, University of Texas Wound classification) [17] and admitted to the surgical ward, RIMS, Imphal, were included in the study. Pregnant and lactating women, patients with S. Creatinine >2 mg/dL, patients with venous ulcers, peripheral arterial diseases, autoimmune and rheumatic diseases, and those unwilling to participate and follow the study protocol were excluded from the study.

Sample size calculation: The sample size was calculated based on the formula:

$$n = \frac{S_1^2 + S_2^2}{e^2}$$

Where s<sub>1</sub>=2.03 {Standard Deviation (SD) for HbA1c}

s\_=0.86 (Standard deviation for HbA1c)

e=L/2, L is the allowable error and equals to 1.7/2

(The values for the standard deviation were taken from a similar study conducted by Zubair M et al.,) [18]

Therefore, 30 patients were included in the study.

#### **Study Procedure**

Clinical examination included palpation of all peripheral pulses, calculation of Ankle Brachial Index (ABPI) using a handheld Doppler machine, and assessment of the ulcer for signs of infection (swelling, exudates, odour, tissue necrosis, crepitation, and pyrexia). Ulcer size was determined by multiplying the maximum and minimum dimensions and expressed in square centimetres. Complete haemogram, fasting and postprandial blood sugar levels, renal function tests, and baseline HbA1c assessment were done at the time of initial presentation.

All the selected patients were divided into two groups. One group comprised patients with DFU with HbA1c  $\leq$ 7% (Group-A), and the other group comprised patients with DFU with HbA1c >7% (Group-B).

Each patient was managed as an inpatient in the ward and followedup until the ulcer was healed or a minimum of 12 weeks, after which the work-up at the initial presentation was reassessed. During the follow-up period, the patient was under strict glycaemic control, ulcer debridement was done in necessary cases, antibiotic therapy started after pus culture and sensitivity report, and wound area assessment was done once a week in all cases.

The wound healing rate in cm<sup>2</sup>/day was calculated using the formula:

Wound area at visit 1-Wound area at subsequent visit


No. of days between the two visits

#### STATISTICAL ANALYSIS

Descriptive and inferential statistical analyses have been carried out in the present study. Results on continuous measurements were presented as Mean±SD, and results on categorical measurements were presented as Number (%). Significance was assessed at a 5% level of significance. Chi-square/Fisher's-exact test was used to find the significance of study parameters on a categorical scale between two or more groups. Student's t-test was used for continuous variables. The statistical software, namely Statistical Package for Social Sciences (SPSS) 22.0 and R environment ver.3.2.2, were used for the analysis of the data.

### RESULTS

The mean age of subjects in Group-A was  $57.33\pm7.43$  years, while in Group-B it was  $56.20\pm7.51$  years (p=0.681) [Table/Fig-1].



The majority of patients (63.3%) had a long history of DM (more than 5 years) in general. When comparing the two groups, 8 (53.3%) patients in Group-A and 11 (73.3%) patients in Group-B had a long duration of diabetes before the development of foot ulcer (p-value of 0.26). The majority (53.3%) had grade I ulcer at presentation, while the remaining (46.7%) had grade II ulcer at presentation. Fisher exact test was used to analyse the data, and with a p-value of 0.715, both groups were evenly matched [Table/Fig-2].

| Parameters                         | Group-A    | Group-B    | Total      | p-value |  |
|------------------------------------|------------|------------|------------|---------|--|
| History of smoking                 |            |            |            |         |  |
| Yes                                | 4 (26.7%)  | 7 (46.7%)  | 11 (36.7%) | 0.256   |  |
| No                                 | 11 (73.3%) | 8 (53.3%)  | 19 (63.3%) |         |  |
| Total                              | 15 (100%)  | 15 (100%)  | 30 (100%)  |         |  |
| History of trauma present or not   |            |            |            |         |  |
| Yes                                | 9 (60%)    | 11 (73.3%) | 20 (66.7%) | 0.439   |  |
| No                                 | 6 (40%)    | 4 (26.7%)  | 10 (33.3%) |         |  |
| Total                              | 15 (100%)  | 15 (100%)  | 30 (100%)  |         |  |
| Duration of diabetes               |            |            |            |         |  |
| More than 5 years                  | 8 (53.3%)  | 11 (73.3%) | 19 (63.3%) | 0.26    |  |
| Less than 5 years                  | 7 (46.7%)  | 4 (26.7%)  | 11 (36.7%) |         |  |
| Total                              | 15 (100%)  | 15 (100%)  | 30 (100%)  |         |  |
| Associated history of hypertension |            |            |            |         |  |
| Present                            | 8 (53.3%)  | 9 (60%)    | 17 (56.7%) | 1       |  |
| Not present                        | 7 (46.7%)  | 6 (40%)    | 13 (43.3%) |         |  |
| Total                              | 15 (100%)  | 15 (100%)  | 30 (100%)  |         |  |
| Duration of ulcer in days          |            |            |            |         |  |
| <10                                | 7 (46.7%)  | 11 (73.3%) | 18 (60%)   | 0.242   |  |
| 10-15                              | 8 (53.3%)  | 4 (26.7%)  | 12 (40%)   |         |  |
| Total                              | 15 (100%)  | 15 (100%)  | 30 (100%)  |         |  |
| Grade of ulcer at presentation     |            |            |            |         |  |
| Grade-I                            | 7 (46.7%)  | 9 (60%)    | 16 (53.3%) | 0.715≠  |  |
| Grade-II                           | 8 (53.3%)  | 6 (40%)    | 14 (46.7%) |         |  |
| Grade-III                          | 0 (0%)     | 0 (0%)     | 0 (0%)     |         |  |
| Total                              | 15 (100%)  | 15 (100%)  | 30 (100%)  |         |  |

| Stage of ulcer at presentation  |            |           |            |        |  |
|---|------------|-----------|------------|--------|--|
| Stage-A   | 1 (6.7%)   | 6 (40%)   | 7 (23.3%)  |        |  |
| Stage-B   | 13 (86.7%) | 9 (60%)   | 22 (73.3%) |        |  |
| Stage-C   | 00         | 00        | 00         | 0.715≠ |  |
| Stage-D   | 1 (6.7%)   | 0 (0%)    | 1 (3.3%)   |        |  |
| Total   | 15 (100%)  | 15 (100%) | 30 (100%)  |        |  |
| <b>[Table/Fig-2]:</b> Distribution of patients according to various factors.<br>#: Fisher's-exact test was used. In rest chi-square test was used |            |           |            |        |  |

The HbA1c value was reassessed after 12 weeks of holistic treatment in both study groups. There was a mean decrease of 0.260 in Group-A and a mean decrease of 1.747 in Group-B. With a p-value of <0.001, the difference was highly significant in Group-B [Table/Fig-3].

The mean ulcer area at presentation in Group-A was 9.59 ( $\pm$ 2.28) cm<sup>2</sup>, while in Group-B it was 10.52 ( $\pm$ 2.32) cm<sup>2</sup>. Student's t-test was used to compare the means, and with a p-value of 0.278, there was no statistically significant difference between the two groups [Table/Fig-3].

| HbA1c%   | At presentation | After 12 weeks | difference | t value | p-value  |
|--|-----------------|----------------|------------|---------|----------|
| Group-A  | 6.49±0.49       | 6.23±0.23      | 0.260      | 3.060   | 0.008**  |
| Group-B  | 10.24±1.71      | 8.49±1.00      | 1.747      | 5.838   | <0.001** |
| [Table/Fig-3]: HbA1c at presentation and after 12 weeks. |                 |                |            |         |          |

The ulcer healing rate per day was calculated by considering the size of the wound on the first visit and subsequent visits, dividing the number of days between the two visits. Wound assessment was done once weekly, and the results showed that the mean healing rate per day was much higher  $(0.09\pm0.02 \text{ cm}^2/\text{day})$  in Group-A patients compared to Group-B  $(0.02\pm0.01 \text{ cm}^2/\text{day})$  patients. Student's t-test was used to compare the means, and with a p-value of <0.001, the difference was highly significant. This confirms authors' hypothesis that Group-A patients would have a much better outcome than Group-B patients in terms of wound healing [Table/Fig-4].

| Variables   | Group-A   | Group-B    | p-value  |  |  |
|---|-----------|------------|----------|--|--|
| Ulcer area (cm²)  | 9.59±2.28 | 10.52±2.32 | 0.278    |  |  |
| Ulcer healing rate (cm²/day)  | 0.09±0.02 | 0.02±0.01  | <0.001** |  |  |
| [Table/Fig-4]: Table showing ulcer area at presentation and daily healing rate in both the group. |           |            |          |  |  |

Student's t-test was us

#### DISCUSSION

The DFU was found to be more common in the 6<sup>th</sup> decade of life, with a mean age of  $56.77\pm7.37$  years, which is similar to the studies conducted by Kumar B et al., and Ravinthar A et al., where the mean age at presentation was  $53.4\pm11.9$  years and 55 years, respectively [19,20]. This comparable mean age may suggest certain timedependent risk factors in the evolution and course of DFU disease that are common to diabetes in any environment. There was a male preponderance in the current study, which is consistent with the results obtained in studies conducted by Christman AL et al., Fesseha BK et al., and Vella L et al., [13,21,22].

In the current study, 36.7% of the patients presented with a history of smoking. Akbar N et al., and Ravinthar A et al., also concluded in their study that smoking has a poor prognosis in patients with foot ulcers [14,20]. Smoking affects the small blood vessels and slows down wound healing. Trauma has been established as one of the important causative factors for DFU [23]. In the study conducted by Kumar B et al., 70% of the patients had a preceding history of trauma.

Hypertension is a risk factor in the disease process of DFU [19]. Ogbuawa O et al., found hypertension to be an independent risk factor for macrovascular disease and subsequent foot ulceration [24]. Many other previously conducted studies have shown conflicting results, with some failing to show any association between blood pressure and DFUs [25-27]. In accordance with the haemodynamic hypothesis, early hyperaemia and capillary hypertension promote more severe late functional abnormalities with increasing duration of diabetes. These late functional abnormalities include loss of autoregulation and reduced hyperemic responses, which interact with the loss of neurogenic flow regulation, disturbed endothelial function, and abnormal rheology to produce the familiar clinical picture of the diabetic foot [28].

The mean HbA1c at presentation in the current study was 8.37 ( $\pm$ 2.27), which is similar to the results reported by Fesseha BK et al., and Shashanka R and Palachandra A [21,29]. However, Kumar B et al., in their study reported a lower mean HbA1c of 6.6 $\pm$ 0.7 [19].

Christman AL et al., and Ravinthar A et al., observed in their studies that patients with low HbA1c values had faster healing [13,20]. Many physiological factors are thought to contribute to poor wound healing in individuals with diabetic foot, including decreased or impaired keratinocyte and fibroblast migration and proliferation, cytokine and growth factor function, angiogenic response, and response to infection. Hyperglycaemia reduces keratinocyte migration and proliferation and contributes to oxidative stress through the production of reactive oxygen [20]. Markuson M et al., in their study, concluded that healing does occur regardless of HbA1c levels, but ulcers in individuals with higher HbA1c levels take significantly longer to heal [30]. However, in a long-term prospective clinicbased study of DFUs conducted by Fesseha BK et al., they did not observe any association between baseline HbA1c and wound healing [21]. Similarly, they concluded that changes in HbA1c measures during wound treatment were generally not associated with accelerated wound healing. However, in the studies by Zubair M et al., and Shashanka R and Palachandra A, it was concluded that slower wound healing is associated with increased HbA1c levels, and HbA1c can be considered as an independent biomarker in assessing wound healing in patients with DFU [18,29]. This is similar to the present study, which showed a strong significance (p-value of <0.001) between HbA1c levels and wound healing.

The present study can help predict the outcome of DFUs in association with HbA1c. A lower HbA1C at presentation and good control of hyperglycaemia would lead to a favourable outcome and better wound healing of the ulcer. A detailed study on the pathogenesis and the relationship of hyperglycaemia with wound healing would lead to a better understanding of this aspect. Studies on the demographic and geographic profiles of other parts of India in relation to the healing of DFUs would also be helpful in such research.

#### Limitation(s)

The follow-up period was short in the present study. Therefore, the findings cannot be generalised to the entire population as it was a single-centre study.

# CONCLUSION(S)

The study demonstrates that HbA1c can be used as a predictive marker for wound healing in patients with DFU. Specifically, the baseline HbA1c value is more effective in predicting the outcome of DFU treatment, particularly in terms of wound healing. Therefore, a lower baseline HbA1c at the presentation of DFU indicates a favourable outcome in terms of wound healing, provided that there are directed efforts to optimise wound healing through comprehensive treatment and follow-up, especially by focusing on bringing diabetes under control to improve conditions for healing.

#### REFERENCES

- Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932-38.
- [2] Marbaniang SP, Chungkham HS, Lhungdim H. A structured additive modeling of diabetes and hypertension in Northeast India. PLoS One. 2022;17(1):e0262560.
- [3] Reiber GE. Epidemiology of foot ulcers and amputations in the diabetic foot. Bowker JH, Pfeifer MA, editors. The Diabetic Foot. 6<sup>th</sup> ed. St. Louis: Mosby; 2001.

Ojing Komut et al., Association of Glycosylated Haemoglobin and Wound Healing in Diabetic Foot Ulcers

- [4] Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. Harris MI, Cowie C, Stern MP, editors. Diabetes in America. 2<sup>nd</sup> ed. Darby: Diane Publishing Co; 1995.
- [5] Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: A systematic review and meta-analysis. Ann Med. 2017;49(2):106-16.
- [6] Laing P. The development and complications of diabetic foot ulcers. Am J Surg. 1998;176(2):11-19.
- [7] Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125(3):217-30.
- [8] Fortington LV, Geertzen JH, van Netten JJ, Postema K, Rommers GM, Dijkstra PU. Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg. 2013;46(1):124-31.
- [9] Bowering CK. Diabetic foot ulcers: Pathophysiology, assessment, and therapy. Can Fam Physician. 2001;47(5):1007-16.
- [10] Clayton W, Elasy TA. A review of pathophysiology, classification and treatment of foot ulcers in diabetic patients. Clin Diabetes. 2009;27(2):52-58.
- [11] Inzucchi S, Bergenstal R, Fonseca V, Gregg E, Mayer-Davis B, Spollett G, et al. American diabetic association; diagnosis and classification of diabetes mellitus. Diabet Care. 2010;33(1):62-69.
- [12] Makris K, Spanou L. Is there a relationship between mean blood glucose and glycated hemoglobin? J Diabetes Sci Technol. 2011;5(6):1572-83.
- [13] Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c is a predicts of healing rate in Diabetic wounds. J Invest Dermatol. 2011;131(10):2121-27.
- [14] Akbar N, Bilal N. Relation of glycemic control with diabetic foot lesions. Int J Path. 2004;2(2):90-93.
- [15] Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Heymsfield SB, et al. HbA1c and lower-extremity Amputation risk in low-income patients with Diabetes. Diabetes Care. 2013;36(11):3591-98.
- [16] International Working Group on the Diabetic Foot. 2015. Available at: http:// iwgdf.org/guidelines/definitionscriteria- 2015. Accessed 30 Jun, 2018).
- [17] Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A comparison of two Diabetic Foot Ulcer classification systems-The Wagner and the University of Texas wound classification systems. Diabetes Care. 2001;24(1):84-88.

- [18] Zubair M, Malik A, Ahmad J. Glycosylated hemoglobin in diabetic foot and its correlation with clinical variables in a north Indian tertiary care hospital. J Diabetes Metab. 2015;6(7):1000571.
- [19] Kumar B, Mishra MK, Sinha A, Soni RK, Patel DK. Prospective study to correlate the level of glycosylated haemoglobin with wound healing, vasculopathy and neuropathy in diabetic foot patients. Int Surg J. 2016;3(4):2087-91.
- [20] Ravinthar A, Saravanan PS, Kesav Phani K. A study of prognostic factors of diabetic foot in relation to plan of management. IOSR-JDMS. 2016;15(11):19-28.
- [21] Fesseha BK, Abularrage CJ, Hines KF, Sherman R, Frost P, Langan S, et al. Association of Hemoglobin A1c and wound healing in diabetic foot ulcers. Diabetes Care. 2018;41(7):1478-85.
- [22] Vella L, Gatt A, Formosa C. Does baseline Hemoglobin A1c level predict diabetic foot ulcer outcome or wound healing time? J AM Podiatr Med Assoc. 2017;107(4):272-79.
- [23] Rosyid FN. Etiology, pathophysiology, diagnosis and management of diabetics' foot ulcer. IJRMS. 2017;5(10):4206-13.
- [24] Ogbuawa O, Williams JT, Henry WL Jr. Diabetic gangrene in black patients. South Med J. 1982;75(3):285-88.
- [25] Gayle E, Pecoraro E, Thomas D. Risk factors for amputation inpatients with patients with diabetes mellitus. Ann Intern Med. 1992;117(2):97-105.
- [26] Rivera ARF. Risk factors for amputation in diabetic patients: A case-control study. Arch Med Res. 1998;29(2):179-84.
- [27] Nelson RG, Gohdes DM, Everhart JE, Hartner JA, Zwemer FL, Pettitt DJ, et al. Lower extremity amputation in non-insulin dependent diabetes. 12 years followup study in Pima Indians. Diabetes Care. 1988;11(1):08-16.
- [28] Flynn MD, Tooke JE. Aetiology of diabetic foot ulceration: A role for the microcirculation? Diabetic Medicine. 1992;9(4):320-29.
- [29] Shashanka R, Palachandra A. Hemoglobin A1c in diabetic foot patients: A predictor of healing rate. IJSS Surgery. 2016;2(3):34-37.
- [30] Markuson M, Hanson D, Anderson J, Langemo D, Hunter S, Thompson P, et al. The relationship between hemoglobin A1c values and healing time for lower extremity ulcers in individuals with diabetes. Adv Skin Wound Care. 2009;22(8):365-72.

#### PARTICULARS OF CONTRIBUTORS:

- 1. Assistant Professor, Department of General Surgery, Tomo Riba Institute of Health and Medical Sciences, Arunachal Pradesh, India.
- 2. Medical Officer, CHC Mebo, East Siang District, Arunachal Pradesh, India.
- 3. Associate Professor, Department of Pharmacology, Tomo Riba Institute of Health and Medical Sciences, Naharlagun, Arunachal Pradesh, India.
- 4. Associate Professor, Department of General Medicine, Tomo Riba Institute of Health and Medical Sciences, Arunachal Pradesh, India.
- 5. Assistant Professor, Department of General Medicine, Tomo Riba Institute of Health and Medical Sciences, Arunachal Pradesh, India.
- 6. Professor, Department of General Surgery, Tomo Riba Institute of Health and Medical Sciences, Arunachal Pradesh, India.
- 7. Assistant Professor, Department of Cardiology, Tomo Riba Institute of Health and Medical Sciences, Arunachal Pradesh, India.
- 8. Associate Professor, Department of Paediatrics, Tomo Riba Institute of Health and Medical Sciences, Arunachal Pradesh, India.

# NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR: Dr. Binita Singha,

Associate Professor, Department of Pharmacology, Tomo Riba Institute of Health and Medical Sciences, Naharlagun-791110, Arunachal Pradesh, India. E-mail: binitasingha2012@gmail.com

#### AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- · Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? Yes
- · For any images presented appropriate consent has been obtained from the subjects. NA

#### PLAGIARISM CHECKING METHODS: [Jain H et al.]

• Plagiarism X-checker: Jun 09, 2023

iThenticate Software: Sep 16, 2023 (15%)

Manual Googling: Aug 30, 2023

ETYMOLOGY: Author Origin EMENDATIONS: 6

Date of Submission: Jun 07, 2023 Date of Peer Review: Aug 11, 2023 Date of Acceptance: Sep 20, 2023

Date of Publishing: Nov 01, 2023